Janux Therapeutics Inc (NASDAQ:JANX)’s traded shares stood at 1.07 million during the last session, with the company’s beta value hitting 3.54. At the close of trading, the stock’s price was $53.41, to imply an increase of 0.19% or $0.1 in intraday trading. The JANX share’s 52-week high remains $65.60, putting it -22.82% down since that peak but still an impressive 89.42% since price per share fell to its 52-week low of $5.65. The company has a valuation of $2.79B, with an average of 0.74 million shares in intraday trading volume over the past 10 days and average of 581.45K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Janux Therapeutics Inc (JANX), translating to a mean rating of 1.18. Of 3 analyst(s) looking at the stock, 0 analyst(s) give JANX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.35.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Janux Therapeutics Inc (NASDAQ:JANX) trade information
After registering a 0.19% upside in the last session, Janux Therapeutics Inc (JANX) has traded red over the past five days. The 5-day price performance for the stock is 6.76%, and 14.56% over 30 days. With these gigs, the year-to-date price performance is 397.76%. Short interest in Janux Therapeutics Inc (NASDAQ:JANX) saw shorts transact 3.46 million shares and set a 5.45 days time to cover.
The extremes give us $42 and $70 for target low and target high price respectively. As such, JANX has been trading -31.06% off suggested target high and 21.36% from its likely low.
Janux Therapeutics Inc (JANX) estimates and forecasts
Looking at statistics comparing Janux Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Janux Therapeutics Inc (JANX) shares are 12.70% up over the last 6 months, with its year-to-date growth rate lower than industry average at 10.61% against 17.50%. Revenue is forecast to shrink -40.00% this quarter before falling -60.00% for the next one. The rating firms project that company’s revenue will grow 45.50% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 830k. Meanwhile, for the current quarter, a total of 9 analyst(s) estimate revenue growth to 790k.
JANX Dividends
Janux Therapeutics Inc has its next earnings report out on 2024-Aug-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
Janux Therapeutics Inc insiders hold 9.07% of total outstanding shares, with institutional holders owning 97.55% of the shares at 107.28% float percentage. In total, 97.55% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P.. As of 2024-06-30, the company held over 9.17 million shares (or 18.6864% of shares), all amounting to roughly $383.95 million.
The next major institution holding the largest number of shares is FMR LLC with 7.78 million shares, or about 15.8566% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $325.8 million.
We also have Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Janux Therapeutics Inc (JANX) shares. Going by data provided on Aug 31, 2024 , Fidelity Growth Company Fund holds roughly 1.23 shares. This is just over 2.37% of the total shares, with a market valuation of $65.93 million. Data from the same date shows that the other fund manager holds a little less at 795.09, or 1.52% of the shares, all valued at about 42.47 million.
